Clinical trials: Human Metapneumovirus Immunization
RSV Infection, Human Metapneumovirus Infection
Safety and Immunogenicity Study of SCB-1022 and SCB-1033 in Healthy Older Adults
This phase 1/2 study will evaluate the safety, reactogenicity and immunogenicity of SCB-1022 and SCB-1033 compared to SCB-1019T (Parts 1 and 2) or Placebo (Part 3).
- Conditions
- RSV Infection, Human Metapneumovirus Infection, Parainfluenza Infection
- Trial name
- NCT06984094
- Testing
- SCB-1019T, SCB-1022, SCB-1033
- Where
- 3 sites in Australia
- Volunteers
- 612 people, healthy volunteers welcome
- Sponsor
- Clover Biopharmaceuticals AUS Pty
Human Metapneumovirus Immunization, Respiratory Syncytial Virus Immunization
Study of a Human Metapneumovirus/Respiratory Syncytial Virus mRNA Vaccine Candidate Encapsulated in a Lipid Nanoparticle-based Formulation in Adults Aged 60 Years and Older
The aim of this study is to evaluate the safety and immunogenicity of a human metapneumovirus (hMPV) / respiratory syncytial virus (RSV) mRNA vaccine candidate encapsulated in a lipid nanoparticle (LNP) based formulation…
- Trial name
- NCT06686654
- Testing
- Investigational hMPV/RSV vaccine, Investigational hMPV vaccine (monovalent), Investigational RSV vaccine (monovalent)
- Where
- 24 sites in United States
- Volunteers
- 1,530 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Respiratory Syncytial Virus Immunization, Human Metapneumovirus Immunization
Phase 1/2 Study of Respiratory Syncytial Virus and Human Metapneumovirus (RSV+HMPV) Vaccine Candidate in Adults 60 Years of Age and Older
This study is a Phase 1/2, randomized, observer-blind, active and placebo-controlled, multi-center study to be conducted in approximately 2400 adults 60 years of age and older.
- Conditions
- Respiratory Syncytial Virus Immunization, Human Metapneumovirus Immunization, Healthy Volunteers
- Trial name
- NCT07734649
- Testing
- RSV+HMPV vaccine, Control Vaccine 3, Control Vaccine 4
- Where
- 50 sites in United States
- Volunteers
- 2,400 people, healthy volunteers welcome
- Sponsor
- Sanofi
Healthy Volunteers, Influenza Vaccination
A Study on the Safety and Immunogenicity of Influenza, Respiratory Syncytial Virus, Human Metapneumovirus and Parainfluenza Vaccines in Adults 18 to 49 Years of Age.
The objective of this study is to evaluate the safety and immunogenicity of different vaccines of hemagglutinin formulations of trivalent influenza vaccine or of a combined respiratory syncytial virus / human metapneumovirus /…
- Conditions
- Healthy Volunteers, Influenza Vaccination, Respiratory Syncytial Virus Vaccination, Parainfluenza Vaccination
- Trial name
- NCT06850051
- Testing
- TIV-HA Vaccine formulation 1 at low dose, TIV-HA formulation 1 at high dose, TIV-HA formulation 2 at low dose
- Where
- 6 sites in Australia
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Sanofi